Neximmune
22 Firstfield Road, Suite 280
Gaithersburg
Maryland
20878
United States
Tel: 301-685-1688
Fax: 240-421-3838
Website: http://www.neximmune.com/
Email: kcarter@neximmune.com
20 articles with Neximmune
-
NexImmune Reports Fiscal Year 2020 Financial Results and Recent Updates
3/31/2021
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today reported its financial results for 2020 and highlighted recent corporate accomplishments
-
NexImmune to Present at the 2021 Barclays Global Healthcare Conference
3/2/2021
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will present a company overview at the virtual 2021 Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 10:55 a.m. Eastern time.
-
NexImmune Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2/17/2021
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response, today announced the closing of its previously announced upsized initial public offering of 7,441,650 shares of its common stock at a price to the public of $17.00 per share
-
NexImmune Announces Pricing of Upsized Initial Public Offering
2/11/2021
NexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology, today announced the pricing of its upsized initial public offering of 6,471,000 shares of its common stock at a price to the public of $17.00 per share.
-
A Look at This Week’s Biotech IPOs
1/22/2021
The 2021 trend of biotech initial public offerings (IPOs) continued this week. Here’s a look. -
Last year was a record number of IPOs in the biotech industry, with 81 raising $13.5 billion. With this kind of a start, 2021 may be scorching.
-
NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&D and Jeffrey Weber as Chief Scientific Advisor
1/4/2021
Both will help NexImmune advance current early-stage clinical trials and will guide Company’s translational efforts to develop new immunotherapy products
-
Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition
12/7/2020
Former Moderna executive and industry veteran brings diverse operational expertise as Oncorus plans buildout of its manufacturing capabilities to support its viral immunotherapy pipeline
-
NexImmune to Highlight Preliminary Results from Phase 1/2 Trial of NEXI-001 via Oral Presentation at 62nd ASH Annual Meeting
11/4/2020
NexImmune announced that an abstract containing preliminary data from its first-in-human study of NEXI-001, a multi-antigen specific CD8+ T cell product, in acute myeloid leukemia patients with relapsed disease has been selected for an oral presentation at the 62nd American Society of Hematology Annual Meeting to be held from December 5-8, 2020.
-
NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia
10/27/2020
NexImmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunotherapies, announced today that it has signed a research initiative related to its AIM nanoparticle technology with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases. City of Hope is a participating clinical site in the ongoing Phase 1/2 study of NEXI-001
-
NexImmune Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of NEXI-001 in Relapsed Acute Myelogenous Leukemia (AML)
9/23/2020
Company is usi n g its Artificial Immune Modulation (AIM) nanoparticle technology to develop T cell immunotherapies for p atients with relapsed and/or refractory hematologic malignancies GAITHERSBURG, Md., Sept. 23, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunotherapies, announced today that it has completed dosing of the first safety cohort (n=3) in its Phase 1/2 clinical trial for NEXI-
-
NexImmune to Present at the Jefferies Virtual Healthcare Conference
6/1/2020
NexImmune, a clinical-stage biopharma company advancing a new generation of nanoparticle-based therapies for targeted immune system response, today announced that John Trainer, Chief Financial Officer, will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 3:30 p.m. Eastern time. About NexImmune’s Lead T Cell Therapy Programs NexImmune’s two lead T cell therapy programs, NEXI-001 and N
-
NexImmune Expands Executive Team with Appointments of Chief Medical Officer and Chief Financial Officer
1/9/2020
NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation nanotechnology platform, announced that industry veterans Han Myint, MD, and John Trainer, MBA, have been appointed as the Company’s Chief Medical Officer and Chief Financial Officer, respectively.
-
NexImmune Appoints Sol Barer as Chairman of the Board of Directors
12/16/2019
NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation (AIM) nanotechnology platform, announced that Sol Barer, PhD has been appointed as the Company’s Chairman of the Board of Directors
-
NexImmune Management to Present at Upcoming Conferences
12/2/2019
NexImmune, a clinical stage immunotherapy company developing novel T cell therapies, announced that Scott Carmer, Neximmune’s Chief Executive Officer, will be particpating and presenting a corporate update at the following conferences
-
NexImmune Receives IND Clearance for Phase 1/2 Trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome
10/31/2019
NexImmune, a clinical stage immunotherapy company developing novel T cell therapies, received Investigational New Drug (IND) clearance for the company’s first cellular therapy product
-
In conjunction with the financing, Tony Yao, MD, PhD, a Partner at ArrowMark Partners, will join NexImmune’s Board of Directors.
-
Neximmune and the Leukemia & Lymphoma Society Enter Partnership for the Development of AIM ACT in AML Patients
10/17/2017
This will advance the Company’s novel cellular immunotherapy into Phase I clinical testing for patients with high risk AML who have relapsed after an allogeneic hematopoietic stem cell transplant.
-
Novel Approach To Adoptive Immunotherapy Developed By Neximmune's Scientific Co-Founders
7/15/2015
-
Neximmune's AIM Immunotherapy Technology Enables Novel Adoptive Immunotherapy Approach For The Treatment Of Cancer
2/25/2014